logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On March 25th, DMALL (02586) spent 4.032 million Hong Kong dollars to repurchase 53,770 shares.

date
19:36 25/03/2026
avatar
GMT Eight
Dapai Intelligence (02586) announced that it will spend 4.032 million Hong Kong dollars to repurchase 53,770 shares on March 25, 2026.
DMALL (02586) announced that it will spend 4.032 million Hong Kong dollars to repurchase 53,770 shares on March 25, 2026.
Related Articles
HK Stock
CT VISION (00994) issues profit warning, expecting shareholders' share of net loss for the year 2025 to be not less than HK$33 million.
HK Stock
WEILI HOLDINGS (02372) releases annual performance, with a net loss attributable to shareholders of 4.1 million yuan, a year-on-year decrease of 56.8%.
HK Stock
From turning point of profit to platform going overseas, the 2025 report reveals the advanced path of Lepubio Biopharma (02157).
CT VISION (00994) issues profit warning, expecting shareholders' share of net loss for the year 2025 to be not less than HK$33 million.
HK Stock
WEILI HOLDINGS (02372) releases annual performance, with a net loss attributable to shareholders of 4.1 million yuan, a year-on-year decrease of 56.8%.
HK Stock
From turning point of profit to platform going overseas, the 2025 report reveals the advanced path of Lepubio Biopharma (02157).
HK Stock
RECOMMEND
“Lobster” Contained: Why The Financial Sector Is Reluctant To Adopt It
“Lobster” Contained: Why The Financial Sector Is Reluctant To Adopt It
icon
25/03/2026
Hong Kong AI New Narrative: Embracing Token Economics
Hong Kong AI New Narrative: Embracing Token Economics
icon
25/03/2026
Is The Spring For Pharma Stocks Here? WuXi AppTec Rises Over 9% As Institutions Back An Industry Inflection
Is The Spring For Pharma Stocks Here? WuXi AppTec Rises Over 9% As Institutions Back An Industry Inflection
icon
25/03/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.